Clinical study of mizoribine for rheumatoid arthritis in our hospital
-
- Nakamura Shinichiro
- Department of orthopaedic surgery, Fukuchiyama city hospital
-
- Tokugawa Seiji
- Department of orthopaedic surgery, Fukuchiyama city hospital
-
- Nakase Masashi
- Department of orthopaedic surgery, Fukuchiyama city hospital
-
- Sakinaga Yasuo
- Department of orthopaedic surgery, Fukuchiyama city hospital
-
- Taniguchi Daigo
- Department of orthopaedic surgery, Ayabe city hospital
Bibliographic Information
- Other Title
-
- 当院における関節リウマチに対するミゾリビンの使用経験
Search this article
Description
In this paper, the clinical effect of mizoribine (new prescription in2009) for rheumatoid arthritis (RA) in our hospital was investigated. Twenty-one patients (10males and11females) were studied. The average age of the patients was 70.3years (ranging from 41to83years). Seventeen patients took 150 mg/day of mizoribine (once a day), two patients took 100 mg/day (once a day) and two remaining patients took 300 mg/week (pulse treatment with methotrexate (MTX). As for the clinical evaluation of mizoribine assessed by DAS28, two patients showed good responses and eight patients had moderate responses whereas eleven patients had no response. The ratio of good and moderate responses in relation to all the patients was47.6%.In the patients over70years old, the ratio was71%. No patients suffered from side effects appeared. Mizoribine might be a good option for rheumatoid arthritis in elderly patients, because it is a well-balanced medicine in terms of safety and efficacy.
Journal
-
- Clinical Rheumatology and Related Research
-
Clinical Rheumatology and Related Research 23 (3), 168-172, 2011
The Japanese Society for Clinical Rheumatology and Related Research
- Tweet
Details 詳細情報について
-
- CRID
- 1390282679317932672
-
- NII Article ID
- 130005113900
-
- ISSN
- 21890595
- 09148760
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- CiNii Articles
-
- Abstract License Flag
- Disallowed